{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 99, "pageCount": 415, "prevPage": 98, "nextPage": 100, "slideType": "nominee_bio", "function": "introduce_nominees", "density": "overcrowded", "nDataPoints": 1, "notes": "The slide uses direct quotes to highlight the expert's negative sentiment and concerns regarding side effects and reimbursement.", "elementsJson": [ "headline_text", "bullet_list", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/99", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-99", "components": [ { "bbox": null, "kind": "callout", "text": "I've been using off-label GLP-1's in this space a little bit recently; lack of discussion among endocrinologists about the drug; only one out of 15 patient families inquired about Vykat.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b29e-a4a85ee5baed", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.07, "y": 0.95 }, "kind": "disclaimer", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4239462b-9ba4-48fa-abf9-915642f2b0dd", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.65 }, "kind": "list", "text": "indicated significant concern about diabetes, edema, and cardiac risks: \"by definition, many of these patients are going to be susceptible to full-blown diabetes...\"", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "822456f5-9a46-4b72-9edf-944e8fc8fe8c", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.18, "w": 0.85, "x": 0.07, "y": 0.21 }, "kind": "list", "text": "Highly skeptical of Vykat with no start forms submitted, calling diazoxide an old, well-known compound, and is wary of side effects and onerous reimbursement effort...", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "8f9a6749-86ef-4d68-aee2-f81a0d1fb06b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.79 }, "kind": "list", "text": "Particularly concerned after we shared color from study investigators with a negative opinion of Vykat, stating that it reinforced his pre-existing skepticism...", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a2bcd58b-6d85-4132-8bf1-9fd0d53b6302", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.22, "w": 0.85, "x": 0.07, "y": 0.41 }, "kind": "list", "text": "indicated that diazoxide \"is a drug that we're familiar with that's been around for a while\" and that best, Vykat would be a secondary option if patients fail GLP-1's...", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a5fc6a5e-16d9-4473-8457-e134b2ddcd0c", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "\"it's a little bit wait and see...I've been using off-label GLP-1's in this space a little bit recently\" — PWS endocrinologist #10. \"I've had a few patients that have responded well, and mechanistically, it does make sense... definitely appetite suppression that's been associated with it... there's a very good usage for it...I've been impressed with the data so far, and I am looking forward to getting more experience with it.\" — PWS endocrinologist #10. \"by definition, many of these patients are going to be susceptible to full-blown diabetes and impaired glucose tolerance... obviously, I don't think it's a miracle drug... hirsutism, that always is an issue...the potential for hyperglycemia...and again, because many of these patients are diabetics to begin with, that is something that there is some concern for that as well...\" — PWS endocrinologist #10. \"I tend to be a little bit suspicious as well\"; \"the thing that concerns me the most is that I was not aware...I had my concerns, but you're giving me a lot more concern that the people who are most in the know and most involved seem to be very, very uncomfortable with it\"; \"the trial itself is small...you're basically making me go back and look at all the data again, because now I'm much more concerned about some of the things that you bring up....\" — PWS endocrinologist #10.", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b29e-abc8277f8ea3", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "PWS endocrinologist #10: Practices throughout the broader New York metro area with 15 PWS patients, in a private practice and community setting.", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "bbec95ec-485f-4dc6-ab3e-b3c4b196a34c", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }